Microbe-Mediated Activation of Toll-like Receptor 2 Drives PDL1 Expression in HNSCC

Jacqueline E Mann1,2, Megan L Ludwig1,3, Aditi Kulkarni1

  • 1Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, MI 48109, USA.

Cancers
|October 13, 2021
PubMed

Insights

Toll-like Receptor 2 (TLR2) drives programmed death-ligand 1 (PDL1) expression in head and neck squamous cell carcinoma (HNSCC). This suggests that bacteria may directly influence cancer immune evasion, impacting immunotherapy effectiveness.

Area of Science:

  • Immunology
  • Oncology
  • Microbiology

Background:

  • Programmed death-ligand 1 (PDL1) checkpoint inhibitors are crucial for treating some head and neck squamous cell carcinoma (HNSCC) patients.
  • Understanding PDL1-mediated immune evasion mechanisms is vital for optimizing HNSCC immunotherapy.

Purpose of the Study:

  • To identify genes and pathways regulating PDL1 expression in HNSCC cells.
  • To investigate the role of Toll-like Receptor 2 (TLR2) in PDL1 modulation within HNSCC models.

Main Methods:

  • Genome-wide CRISPR screening was employed to identify PDL1 regulatory factors in an HNSCC cell line.
  • Experiments involved gene depletion, interferon-γ induction, and TLR2 stimulation with bacterial components (Staphylococcus aureus, Pam3CSK4).

Main Results:

  • Toll-like Receptor 2 (TLR2) was identified as a key regulator of PDL1 expression in HNSCC.
  • TLR2 depletion inhibited interferon-γ-induced PDL1 expression.
  • TLR2 stimulation enhanced PDL1 expression in multiple HNSCC models.

Conclusions:

  • Toll-like Receptor 2 (TLR2) plays a significant role in modulating PDL1 expression in head and neck squamous cell carcinoma.
  • Microbiota may directly influence cancer immunosuppression by affecting PDL1 expression.
  • Further research is needed to explore the HNSCC microbiome's impact on immunotherapy outcomes.